Drug news
FDA approves Opana ER from Endo Pharma for Moderate to Severe Pain
The FDA has approved a new, harder-to-abuse formulation of Opana ER, the extended-release oxymorphone drug that is crush resistant from Endo Pharma for Moderate to Severe Pain. There have been generic versions of immediate release and extended release oxymorphone on the market for many years. The Endo Pharma version is distinguished by its "harder ro abuse " formulation which is patent protected until 2023.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins